Cetera Advisors LLC Has $301,000 Stock Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (2024)

Posted by Defense World Staff on Aug 16th, 2024

Cetera Advisors LLC increased its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 18.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 60,139 shares of the biotechnology company’s stock after purchasing an additional 9,547 shares during the quarter. Cetera Advisors LLC’s holdings in Aurinia Pharmaceuticals were worth $301,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AUPH. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $2,089,000. GSA Capital Partners LLP grew its holdings in Aurinia Pharmaceuticals by 196.1% during the 1st quarter. GSA Capital Partners LLP now owns 349,204 shares of the biotechnology company’s stock worth $1,750,000 after acquiring an additional 231,260 shares during the period. Armistice Capital LLC raised its position in shares of Aurinia Pharmaceuticals by 57.7% during the 4th quarter. Armistice Capital LLC now owns 9,536,000 shares of the biotechnology company’s stock valued at $85,729,000 after acquiring an additional 3,488,000 shares during the last quarter. Capstone Investment Advisors LLC bought a new position in shares of Aurinia Pharmaceuticals in the 1st quarter worth $158,000. Finally, Nordea Investment Management AB boosted its position in shares of Aurinia Pharmaceuticals by 51.7% in the 1st quarter. Nordea Investment Management AB now owns 308,500 shares of the biotechnology company’s stock worth $1,552,000 after purchasing an additional 105,100 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, StockNews.com raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Read Our Latest Stock Analysis on Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Stock Performance

AUPH stock opened at $5.59 on Friday. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.24. The company has a current ratio of 5.60, a quick ratio of 5.05 and a debt-to-equity ratio of 0.19. The firm has a market cap of $797.49 million, a PE ratio of -13.00 and a beta of 1.44. The business’s 50-day moving average price is $5.55 and its two-hundred day moving average price is $5.61.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share for the quarter, meeting the consensus estimate of $0.01. Aurinia Pharmaceuticals had a negative return on equity of 11.75% and a negative net margin of 24.31%. The business had revenue of $57.10 million for the quarter, compared to analysts’ expectations of $54.25 million. During the same quarter in the previous year, the business posted ($0.08) EPS. Aurinia Pharmaceuticals’s revenue for the quarter was up 37.6% on a year-over-year basis. As a group, research analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.15 earnings per share for the current year.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, insider Scott Michael Habig sold 18,249 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total transaction of $96,902.19. Following the completion of the sale, the insider now owns 456,338 shares of the company’s stock, valued at $2,423,154.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Profile

(Free Report)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

You might be interested in:

Cetera Advisors LLC Invests $297,000 in Global X Millennial Consumer ETF